Display options
Cite
Ogawa N, Inokuchi M, Takagi Y, et al. Clinical significance of platelet derived growth factor-C and -D in gastric cancer. Oncol Lett. 2015;10(6):3495-3501doi: 10.3892/ol.2015.3758.
Ogawa, N., Inokuchi, M., Takagi, Y., Sugita, H., Kato, K., Kojima, K., & Sugihara, K. (2015). Clinical significance of platelet derived growth factor-C and -D in gastric cancer. Oncology letters, 10(6), 3495-3501. https://doi.org/10.3892/ol.2015.3758
Ogawa, Norihito, et al. "Clinical significance of platelet derived growth factor-C and -D in gastric cancer." Oncology letters vol. 10,6 (2015): 3495-3501. doi: https://doi.org/10.3892/ol.2015.3758
Ogawa N, Inokuchi M, Takagi Y, Sugita H, Kato K, Kojima K, Sugihara K. Clinical significance of platelet derived growth factor-C and -D in gastric cancer. Oncol Lett. 2015 Dec;10(6):3495-3501. doi: 10.3892/ol.2015.3758. Epub 2015 Sep 29. PMID: 26788156; PMCID: PMC4665846.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2015 Dec;10(6):3495-3501. doi: 10.3892/ol.2015.3758. Epub 2015 Sep 29.

Clinical significance of platelet derived growth factor-C and -D in gastric cancer.

Oncology letters

Norihito Ogawa, Mikito Inokuchi, Yoko Takagi, Hirofumi Sugita, Keiji Kato, Kazuyuki Kojima, Kenichi Sugihara

Affiliations

  1. Department of Surgical Oncology, Graduate School, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
  2. Department of Translational Oncology, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.
  3. Center for Minimally Invasive Surgery, Tokyo Medical and Dental University, Tokyo 113-8519, Japan.

PMID: 26788156 PMCID: PMC4665846 DOI: 10.3892/ol.2015.3758

Abstract

Platelet-derived growth factor (PDGF)-C and PDGF-D are frequently upregulated in human cancers and play important roles in tumor progression, angiogenesis and metastasis. However, the distribution, frequency and prognostic value of PDGF-C and PDGF-D expression in gastric cancer have not been clarified. The present study evaluated the association between expression of PDGF-C and PDGF-D, clinicopathological factors and outcomes, in patients with gastric cancer. Gastric adenocarcinoma tumor samples were obtained from 204 patients who underwent curative gastrectomy between 2003 and 2007. The expression of PDGF-C and PDGF-D was analyzed by immunohistochemical staining. High expression of PDGF-C and PDGF-D was detected in 114 (56%) and 151 (74%) tumors, respectively. PDGF-D expression was significantly associated with tumor depth (P=0.039), histopathology (P<0.01), tumor stage (P=0.01) and recurrence (P<0.01), whereas PDGF-C expression correlated only with histopathology (P=0.05). High PDGF-D expression was also associated with significantly shorter relapse-free survival (RFS) time (P<0.01), whilst high PDGF-C expression was associated with marginally, but not significantly, shorter RFS (P=0.10). On multivariate analysis, high PDGF-D expression was determined to be an independent prognostic factor (hazard ratio, 3.3; 95% confidence interval, 1.20-9.4; P=0.02). These findings indicate that high PDGF-D expression is strongly associated with tumor progression, recurrence, distant metastasis and poor outcomes in patients with gastric cancer. PDGF-D may therefore be an independent prognostic factor and a novel therapeutic target.

Keywords: gastric cancer; platelet-derived growth factor C; platelet-derived growth factor D; prognosis

References

  1. Stem Cells. 2009 Aug;27(8):1712-21 - PubMed
  2. Clin Cancer Res. 2012 Nov 1;18(21):5992-6000 - PubMed
  3. Crit Rev Oncol Hematol. 2009 Aug;71(2):127-64 - PubMed
  4. Clin Cancer Res. 2006 May 1;12(9):2676-88 - PubMed
  5. Cancer Sci. 2009 Feb;100(2):310-5 - PubMed
  6. J Clin Oncol. 2011 Aug 1;29(22):3030-6 - PubMed
  7. Ann Oncol. 2005 Feb;16(2):273-8 - PubMed
  8. Clin Cancer Res. 2008 Dec 1;14(23):7843-9 - PubMed
  9. Lancet Oncol. 2008 Mar;9(3):215-21 - PubMed
  10. Lancet Oncol. 2013 May;14 (6):481-9 - PubMed
  11. Cancer Res. 2004 Mar 1;64(5):1722-9 - PubMed
  12. Cancer Res. 2005 Jul 1;65(13):5711-9 - PubMed
  13. Cancer Res. 2002 May 1;62(9):2468-73 - PubMed
  14. Ann Surg Oncol. 2003 Apr;10(3):234-41 - PubMed
  15. Cancer Res. 2008 Mar 15;68(6):1927-34 - PubMed
  16. Oncogene. 2002 May 30;21(24):3847-54 - PubMed
  17. Cancer Res. 2009 Jan 1;69(1):369-78 - PubMed
  18. Nat Cell Biol. 2001 May;3(5):517-21 - PubMed
  19. Cancer Res. 2007 Dec 1;67(23):11377-85 - PubMed
  20. Mol Cell Biol. 2005 Jul;25(14):6279-88 - PubMed
  21. J Clin Oncol. 2011 Oct 20;29(30):3968-76 - PubMed
  22. Biochim Biophys Acta. 2007 Sep;1772(9):1033-40 - PubMed
  23. Histopathology. 2008 May;52(6):738-46 - PubMed
  24. Cancer Res. 2002 Jul 1;62(13):3729-35 - PubMed
  25. Ann Surg Oncol. 2008 Jan;15(1):69-79 - PubMed
  26. Genes Dev. 2008 May 15;22(10):1276-312 - PubMed
  27. Stem Cells. 2008 Jun;26(6):1425-35 - PubMed
  28. Oncol Rep. 2006 Jan;15(1):65-71 - PubMed
  29. Contemp Oncol (Pozn). 2013;17(2):150-5 - PubMed
  30. Lancet Oncol. 2013 May;14(6):490-9 - PubMed
  31. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  32. Cancer Biol Ther. 2010 Jan;9(1):42-8 - PubMed
  33. J Cell Physiol. 2013 Mar;228(3):556-62 - PubMed
  34. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed
  35. J Clin Oncol. 2006 Jan 10;24(2):228-40 - PubMed

Publication Types